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AbSTrACT
Objective the primary objective was to study 
the risk of acute myocardial infarction (aMi) and 
coronary heart disease (chD) in patients with familial 
hypercholesterolaemia (Fh) and compare with the risk in 
the general population.
Methods Patients with an Fh mutation but without 
prior aMi (n=3071) and without prior chD (n=2795) 
were included in the study sample during 2001–2009. 
We obtained data on all aMi and chD hospitalisations 
in norway. We defined incident cases as first time 
hospitalisation or out-of-hospital death due to aMi 
or chD. We estimated standardised incidence ratios 
(sirs) with 95% cis with indirect standardisation using 
incidence rates for the total norwegian population 
stratified by sex, calendar year and 1 year age groups as 
reference rates.
results sirs for aMi (95% cis) were highest in the age 
group 25–39 years; 7.5 (3.7 to 14.9) in men and 13.6 
(5.1 to 36.2) in women and decreased with age to 0.9 
(0.4 to 2.1) in men and 1.8 (0.9 to 3.7) in women aged 
70–79 years. similarly, sirs for chD were highest among 
patients 25–39 years old; 11.1 (7.1–17.5) in men and 
17.3 (9.6–31.2) in women and decreased 2.4 (1.4–4.2) 
in men and 3.2 (1.5–7.2) in women at age 70–79. 
For all age groups, combined sirs for chD were 4.2 
(3.6–5.0) in men and 4.7 (3.9–5.7) in women.
Conclusion Patients with Fh are at severely increased 
risk of aMi and chD compared with the general 
population. the highest excess risk was in the youngest 
group aged 25–39 years, in both sexes.
InTrOduCTIOn
Heterozygous familial hypercholesterolaemia (FH) 
is an inherited condition with elevated circulating 
low-density lipoprotein levels from birth.1 2 It affects 
approximately one in every 200–300 people3 4 and 
increases the risk of premature coronary heart 
disease (CHD).5–10 Patients with FH are recom-
mended a healthy lifestyle and statin treatment from 
age 8 to 10 years,11 12 but uncertainty remains about 
any residual risk in treated subjects.4 13–17 Large 
cohorts and long follow-up are needed to generate 
such data, which is difficult to establish for FH.18 In 
one large cohort study, the relative risk for coronary 
mortality in patients aged 20–59 declined from an 
8-fold increased risk prior to statins became avail-
able to 3.7-fold thereafter.13 The primary aim of the 
present study was to relate the incidence of acute 
myocardial infarction (AMI) and CHD per year in 
the complete cohort of all patients with genetically 
proven FH in Norway to the incidence of these 
diseases in the total Norwegian population of about 
5 million people. We used standardised incidence 
ratios (SIRs) during 2001–2009 for the primary 
aim. The secondary aim was to estimate SIRs for 
the associated procedures: percutaneous coronary 
intervention (PCI), coronary artery bypass grafting 
(CABG) and total coronary revascularisation (CR) 
procedures during the same period.
MeThOdS
Study design
This is a registry-based prospective cohort study 
of all genotyped patients with FH in Norway. The 
study was perfomed according to the protocol 
approved in 2011 (supplementary file 1). We 
followed all patients who were included in the Unit 
for Cardiac and Cardiovascular Genetics (UCCG) 
Registry at 31 December 2009 for first time inci-
dent AMI and CHD events as well as first-time 
event of PCI, CABG and total CR during the period 
2001 throughout 2009.
Patient involvement
We planned and discussed the study in meetings 
with the patient organisation for patients with FH 
in Norway who informed their members through a 
bi-annual paper magazine sent to all members.
uCCG registry
All patients with genetically diagnosed FH in 
Norway are included in the National UCCG 
Registry after written informed consent. Prior to 
the registry linkage all patients received a letter 
and were offered to be removed from the list and 
not participate in the registry linkage (supplemen-
tary file 2). At 31 December 2009, there were 
4273 patients with FH registered of whom 8 were 
homozygous and of whom 3 had CHD.19 Sex, 
birth year, date and age of genetic diagnosis were 
extracted from the registry. The frequency of the 
most common mutations in the cohort and the 
registry is further described elsewhere.20–22 After 
the time of diagnosis, total serum cholesterol mean 
(SD) was 220 (58) mg/dL (5.7 (1.5) mmol/L), 
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low-density lipoprotein cholesterol (LDL-C) was 151 (50) mg/
dL (3.9 (1.3) mmol/L) and 89.1% used lipid-lowering drugs in 
the cohort.20
Cardiovascular outcomes and data linkage
We obtained data on all hospitalisations in Norway during 
1994–2009 for AMI, CHD, PCI, CABG and total CR from the 
Cardiovascular Disease in Norway project (CVDNOR, http://
www. cvdnor. no), a collaborative project between the Univer-
sity of Bergen and the Norwegian Knowledge Centre for the 
Health Services. Patient’s sex, age, date and time of admission 
and discharge, discharge diagnoses and diagnostic and surgical 
procedures are included in the database. We obtained data on 
death from the Norwegian Cause of Death Registry (NCoDR) 
containing information on date and cause of death (underlying, 
contributing and immediate causes) for all deaths among Norwe-
gian residents.
We followed patients for endpoints through linkage with the 
NCoDR and CVDNOR by using the unique personal identifi-
cation number for each Norwegian resident. Data were given 
according to the International Classification of Diseases, version 
9 (ICD9) or version 10 (ICD10). Definition of AMI is the ICD9 
code 410 or the ICD10 codes I21 and I22. CHD is defined as the 
ICD9 codes 410–414 or ICD10 codes I20–I25.
An incident event of AMI is defined as a hospitalisation with 
AMI as main or supplementary diagnosis or a death with CHD 
as the underlying cause of death without any prior hospitalisa-
tions with AMI. During 1994–2009, the definition of AMI in 
Norway changed. During the 1990s, the WHO criteria of 1979 
for AMI was used.23 From 2000, AMI was defined according to 
the new American College of Cardiology/European Society of 
Cardiology definition.24 In 2007, the Universal Definition of MI 
was implemented.25
We defined an incident event of CHD as a hospitalisation with 
CHD as main or secondary diagnosis or a death with CHD as 
the underlying cause of death without any prior hospitalisations 
with CHD.
PCI was defined as code FNG in the Nordic Medico-Statis-
tical Committee (NOMESCO) classification of medical (NCMP) 
and surgical (NCSP) code FNG or as codes 3294, 3236 or 3239 
in the Norwegian classification of medicinal procedures; third 
edition, 1995 (SIF-95). CABG definition is NCMP/NCSP codes 
FNA–FNF or codes 3112–3129 in SIF-95. Total CR definition 
is NCMP/NCSP codes FNA–FNG and codes 3112–3129, 3294, 
3236 and 3238 in SIF-95.
To analyse the first time events, we required 7 years of observa-
tion free of events prior to the start of follow-up. Patients regis-
tered in the UCCG later than 31 December 2009 and patients 
with any endpoint in question before 2001 were excluded from 
the analyses. Previous studies have shown that a washout period 
of 7 years results in only 3%–4% overestimation of incident 
events of AMI.26
We counted events among patients with FH from after the day 
they were included in the UCCG register and calculated the inci-
dence of first occurrence of the endpoint in question, death from 
other causes or end of follow-up, whichever came first, during 
the period 1 January 2001 to 31 December 2009 for patients 
with FH and the entire Norwegian population. The follow-up 
time for each individual was split over calendar years and the 
attained age for each individual was updated for each calendar 
year.
Statistical analysis
We calculated unadjusted incidence rates for each endpoint 
in 2001–2009 stratified by sex and age. For each age stratum, 
the incidence rates were calculated as the number of events 
per 1000 person-years of follow-up for patients with FH and 
the entire population. We calculated SIRs for each endpoint 
using indirect standardisation with incidence rates for the total 
Norwegian population as reference rates.27 Expected number 
of incident events was calculated for each combination of 
1 year age group and calendar year in the UCCG Registry as 
time spent in the cohort multiplied by the incidence rate for 
the same combination of birth year and calendar year in the 
total Norwegian population. Calculations were performed for 
men and women separately and in combination. Total expected 
number of incident events for men and women were obtained 
by summing expected number of events over 1 year age groups 
and calendar years.
SIR was calculated as the observed number of events divided by 
the expected number of events. Confidence limits were obtained 
using the normal approximation to the Poisson distribution.
Linear trend in SIR for AMI and CHD across calendar 
periods (2001–2003, 2004–2006 and 2007–2009) were tested 
using orthogonal polynomial contrasts after Poisson regression 
models with observed number of events as the outcome, the 
logarithm of expected number of events as offset and calendar 
period as a three-level factor variable. P <0.05 were considered 
statistically significant. All analyses were performed using Stata 
V.14.
Table 1 Characteristics of the patients with familial 
hypercholesterolaemia (FH) in the Unit for Cardiac and Cardiovascular 
Genetics (UCCG) Registry
Variables Total Men Women
Total FH study sample*, n 4273 2062 2211
  Age at inclusion†, mean (SD) 32.7 (18.6) 31.2 (18.1) 34.1 (18.9)
Study sample with incident AMI‡
  No of patients with FH 
included in analyses of 
incident AMI
3071 1394 1677
  No of patients with FH with 
first time AMI event
99 65 34
  Age at time of first AMI event, 
mean (SD)
56.2 (13.4) 54.1 (12.9) 60.1 (13.7)
  Years since inclusion in the 
UCCG Registry to first time 
AMI event, mean (SD)
5.9 (4.8) 5.9 (4.9) 5.9 (4.6)
Study sample with incident CHD§
  No of patients with FH 
included in analyses of 
incident CHD
2795 1227 1568
  No of patients with FH with 
first time CHD event
253 142 111
  Age at time of first CHD event, 
mean (SD)
55.1 (13.0) 53.1 (12.4) 57.7 (13.7)
  Years since inclusion in the 
UCCG Registry to first time 
CHD event, mean (SD)
6.2 (5.0) 6.3 (5.3) 6.2 (4.6)
*The study sample in the UCCG Registry during 1992–2009.
†Age at inclusion in the UCCG Registry equals time at verified genetic FH diagnosis.
‡The study sample in the UCCG Registry with incident acute myocardial infarction 
(AMI) event during 2001–2009.
§The study sample in the UCCG Registry with incident coronary heart disease (CHD) 
event during 2001–2009.
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reSulTS
Table 1 shows the characteristics of the study sample. Mean 
(SD) age at the time of genetic diagnosis was 32.7 (18.6) years, 
31.2 (18.1) years for men versus 34.1 (18.9) years for women 
(P<0.001).
We excluded 1069 of the 4273 patients registered because 
they were below 25 years of age during the complete follow-up 
period for accurate calculation of CHD. Further, we excluded 
329 because they had an event before inclusion in the registry 
and 80 patients because they had an event during the 7-year 
wash-out period prior to 2001. Thus, we analysed a cohort of 
2795 patients for their first incident CHD during 2001–2009.
Likewise, for MI calculations, we excluded 1069 patients 
younger than 25 years during the study period, 108 had an 
AMI event before inclusion in the registry and 25 had their first 
AMI event in the wash-out period, leaving a cohort of 3071 
patients for analyses of incident AMI.
Mean (SD) age at first AMI and CHD event were 56.2 (13.4) 
and 55.1 (13.0) years, respectively. Tables 2 and 3 show the 
SIRs for AMI and CHD in patients with FH according to sex, 
and figure 1 shows the SIRs for AMI and CHD for both sexes 
combined. In total, SIR for AMI (95% CI) was 2.3 (1.8–3.0) in 
men and 2.3 (1.6–3.2) in women. SIR for CHD (95% CI) was 
4.2 (3.6–5.0) in men and 4.7 (3.9–5.7) in women. Both the 
SIRs for AMI and CHD were highest in the youngest age group 
25–39 years in both sexes.
Mean (SD) time from inclusion in the UCCG Registry to the 
first AMI or CHD event were 5.9 (4.8) and 6.2 (5.0) years, 
Table 2 Acute myocardial infarction during 2001–2009
Sex and age groups Incident cases Person years in 1000
Crude incidence rate per 1000 
person years (95% CI) expected number of cases* SIr (95% CI)*
Men
  25–39 8 3.1 2.6 (1.3 to 5.1) 1.07 7.5 (3.7 to 14.9)
  40–49 18 2.1 8.4 (5.3 to 13.4) 4.25 4.2 (2.7 to 6.7)
  50–59 15 1.5 9.7 (5.8 to 16.1) 7.94 1.9 (1.1 to 3.1)
  60–69 18 0.9 19.9 (12.5 to 31.5) 8.30 2.2 (1.4 to 3.4)
  70–79 5 0.3 15.1 (6.3 to 36.3) 5.71 0.9 (0.4 to 2.1)
  80+ 1 0.0 65.0 (9.2 to 460) 0.43 2.33 (0.3 to 16.5)
  Total 65 8.1 8.1 (6.3 to 10.3) 27.7 2.3 (1.8 to 3.0)
Women
  25–39 4 3.5 1.1 (0.4 to 3.0) 0.3 13.6 (5.1 to 36.2)
  40–49 3 2.4 1.3 (0.4 to 3.9) 1.1 2.7 (0.96 to 8.3)
  50–59 10 2.0 5.1 (2.7 to 9.4) 2.6 3.8 (2.0 to 7.1)
  60–69 7 1.2 6.0 (2.9 to 12.6) 3.8 1.9 (0.9 to 3.9)
  70–79 8 0.5 16.2 (8.1 to 32.4) 4.3 1.8 (0.9 to 3.7)
  80+ 2 0.1 16.2 (4.1 to 64.8) 2.8 0.7 (0.2 to 2.8)
  Total 34 9.7 3.5 (2.5 to 4.9) 15.0 2.3 (1.6 to 3.2)
Statistically significant results in bold.
*Age-standardised by indirect standardisation with reference rates for the total Norwegian population during 2001–2009 stratified by sex, calendar year and 1 year age groups.
SIR, standardised incidence ratio.
Table 3 Coronary heart disease during 2001–2009
Sex and age groups Incident cases Person years in 1000
Crude incidence rate per 1000 
person years (95% CI)
expected number of 
cases* SIr (95% CI)*
Men
  25–39 19 3.04 6.3 (4.0 to 9.8) 1.7 11.1 (7.1 to 17.5)
  40–49 43 1.86 23.1 (17.2 to 31.2) 6.5 6.7 (4.9 to 9.0)
  50–59 34 1.09 31.2 (22.3 to 43.6) 10.4 3.3 (2.3 to 4.6)
  60–69 31 0.53 58.9 (41.4 to 83.7) 9.4 3.3 (2.3 to 4.7)
  70–79 13 0.17 76.3 (44.3 to 131.5) 5.4 2.4 (1.4 to 4.2)
  80+ 2 0.01 346.9 (86.8 to 1387.3) 0.2 9.1 (2.3 to 36.5)
  Total 142 6.769 21.2 (18.0 to 25.0) 33.6 4.2 (3.6 to 5.0)
Women
  25–39 11 3.47 3.2 (1.9 to 5.7) 0.6 17.3 (9.6 to 31.2)
  40–49 23 2.26 10.0 (6.7 to 15.1) 2.6 8.7 (5.8 to 13.1)
  50–59 27 1.73 15.6 (10.7 to 22.7) 6.0 4.5 (3.1 to 6.6)
  60–69 22 0.91 24.2 (15.9 to 36.72 7.1 3.1 (2.0 to 4.7)
  70–79 22 0.31 72.1 (47.4 to 109.4) 5.4 4.1 (2.7 to 6.2)
  80+ 6 0.06 105.7 (47.5 to 235.2) 1.9 3.2 (1.5 to 7.2)
  Total 111 8.8 12.7 (10.5 to 15.3) 23.6 4.7 (3.9 to 5.7)
Statistically significant results in bold. 
*Age-standardised by indirect standardisation with reference rates for the total Norwegian population during 2001–2009 stratified by sex, calendar year and 1 year age groups.
SIR, standardised incidence ratio.
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Figure 1 Standardised incidence ratios (SIRs) with 95% CIs for acute myocardial infarction (AMI) and coronary heart disease (CHD) in patients with 
familial hypercholesterolaemia during 2001–2009. Age-standardised and sex-standardised within each age group.
Figure 2 Trends in standardised incidence ratios (SIRs) for acute myocardial infarction (AMI) and coronary heart disease (CHD) in patients with 
familial hypercholesterolaemia during 2001–2009. (A) Trend in SIRs (95% CI) for CHD in men. (B) Trend in SIRs (95% CI) for CHD in women. (C) Trend 
in SIRs (95% CI) for CHD in both sexes. (D) Trend in SIRs (95% CI) for AMI in men. (E) Trend in SIRs (95% CI) for AMI in women. (F) Trend in SIRs 
(95% CI) for AMI in both sexes.
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respectively, suggesting a mean duration of lipid-lowering treat-
ment prior to event of about 6 years.
Figure 2 displays the trends in SIRs according to sex and 
calendar period. For AMI, no significant trends over time were 
found (P=0.21 for both sexes combined, P=0.78 in men and 
P=0.08 in women). For CHD, there was a significant decrease 
over time for both sexes combined (P=0.03) and for men 
(P=0.02), but not for women (P=0.46).
The SIRs for PCI, CABG and total CR procedures were clearly 
higher in younger than in older patients as shown in tables 4, 5 
and 6.
dISCuSSIOn
We observed an increased risk of AMI and CHD in FH compared 
with the general population. Importantly, the youngest age group 
had the highest excess risk in both sexes including the need for 
PCI, CABG and total CR. Both the Simone Broome Register 
Group and us have previously reported an increased risk for 
CHD death before the age of 40.13 28 As recently shown,14 our 
study show the severity of carrying an FH mutation in both sexes 
and particularly at young age.
We previously reported that 88% of the Norwegian patients 
with FH who died actually used statins at time of death but 
still with too high LDL-C.15 Statins were used by 89.1% of the 
Norwegian FH population as studied in 2006 (n=956),20 and 
it is reasonable to estimate that about 90% of the present study 
cohort used statins. Taken together with other recent studies, 
this emphasises the importance of early diagnosis and treatment 
in FH.29 30
During the observation period, SIR for CHD decreased 
slightly in men but not in women indicating a particular need 
to focus attention on the excess risk in young FH women. 
Statins were used for 6 years or more in those who experienced 
Table 4 Percutaneous coronary intervention during 2001–2009
Sex and age groups Incident cases Person years in 1000
Crude incidence rate per 1000 
person years (95% CI)
expected number of 
cases* SIr (95% CI)*
Men
  25–39 9 3.1 2.9 (1.5 to 5.5) 0.6 14.5 (7.5 to 27.8)
  40–49 21 2.1 9.8 (6.4 to 15.0) 3.3 6.3 (4.1 to 9.7)
  50–59 30 1.5 20.6 (14.4 to 29.5) 6.3 4.8 (3.3 to 6.8)
  60–69 16 0.8 19.0 (11.6 to 31.0) 5.7 2.8 (1.7 to 4.6)
  70–79 7 0.3 22.3 (10.6 to 46.7) 2.6 2.7 (1.3 to 5.7)
  80+ 2 0.0 94.3 (23.6 to 377.0) 0.1 18.3 (4.6 to 73.0)
  Total 85 7.9 10.8 (8.7 to 13.3) 18.6 4.6 (3.7 to 5.6)
Women
  25–39 2 3.5 0.6 (0.1 to 2.3) 0.2 12.1 (3.0 to 48.5)
  40–49 10 2.4 4.2 (2.3 to 7.8) 0.8 13.2 (7.1 to 24.5)
  50–59 13 1.9 6.7 (3.9 to 11.5) 2.0 6.6 (3.8 to 11.4)
  60–69 14 1.1 12.3 (7.3 to 20.9) 2.5 5.5 (3.3 to 9.3)
  70–79 6 0.5 12.8 (5.8 to 28.6) 1.7 3.6 (1.6 to 7.9)
  80+ 0 0.1 0 0.3
  Total 45 9.6 4.7 (3.5 to 6.3) 7.4 6.1 (4.5 to 8.1)
Statistically significant results in bold. 
*Age-standardised by indirect standardisation with reference rates for the total Norwegian population during 2001–2009 stratified by sex, calendar year and 1 year age groups.
SIR, standardised incidence ratio.
Table 5 Coronary artery bypass grafting during 2001–2009
Sex and age groups Incident cases Person years in 1000
Crude incidence rate per 1000 person 
years (95% CI)
expected number of 
cases* SIr (95% CI)*
Men
  25–39 3 3.2 0.9 (0.3 to 2.9) 0.3 10.7 (3.5 to 33.3)
  40–49 16 2.2 7.2 (4.4 to 11.8) 1.6 10.1 (6.2 to 16.6)
  50–59 12 1.6 7.7 (4.4 to 13.5) 3.3 3.6 (2.0 to 6.3)
  60–69 11 0.9 12.8 (7.1 to 23.1) 3.2 3.5 (1.9 to 6.3)
  70–79 5 0.3 17.2 (7.2 to 41.4) 1.3 3.8 (1.6 to 0.2)
  80+ 1 0.03 35.4 (5.0 to 251.4) 0.1 12.9 (1.8 to 91.8)
  Total 48 8.1 5.9 (4.4 to 7.8) 9.7 4.9 (3.7 to 6.5)
Women
  25–39 1 3.5 0.3 (0.0 to 2.0) 0.1 12.4 (1.7 to 88.1)
  40–49 3 2.4 1.3 (0.4 to 3.9) 0.3 8.6 (2.8 to 26.6)
  50–59 5 2.0 2.5 (1.0 to 6.0) 1.0 5.1 (2.1 to 12.3)
  60–69 5 1.2 4.3 (1.8 to 10.2) 1.3 3.7 (1.5 to 8.9)
  70–79 9 0.5 19.5 (10.2 to 37.5) 0.8 10.8 (5.6 to 20.7)
  80+ 0 0.1 0 0.1 –
  Total 23 9.7 2.4 (1.6 to 3.6) 3.7 6.2 (4.1 to 9.3)
Statistically significant results in bold. 
*Age-standardised by indirect standardisation with reference rates for the total Norwegian population during 2001–2009 stratified by sex, calendar year and 1 year age groups.
SIR, standardised incidence ratio.
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an event assuming that treatment was initiated at the time 
of genetic diagnosis. However, the mean age of genetic diag-
nosis was 32.7 years, unfortunately too late. A previous study 
reported a near normalisation of CHD risk in statin-treated 
patients older than 55 years, in fact they observed a risk of 
MI approaching that of the general population.17 Importantly, 
the present study add new information on the risk in young 
patients with FH. Any excess risk in young patients cannot be 
detected in a study of patients older than 55 years, and here 
we report a particularly high excess risk in patients with FH 
younger than 40 years.
We observed a significant reduction in the trend for CHD in 
patients with FH on top of the reduction in the general popula-
tion (figure 2). However, trends in SIRs for CHD decreased only 
in men with FH, not women, suggesting that young women with 
FH need particular attention.
Strengths and limitations
Important strengths were the high number of genotyped 
patients with FH and the complete follow-up. All AMI and 
CHD hospitalisations and the corresponding reported deaths 
from the NCoDR for the entire Norwegian population during 
2001–2009 were included. However, patients with FH who died 
before genetic testing were not registered.
Data on all hospitalisations in Norway were included in the 
analyses, but patients not hospitalised due to, for example, 
misdiagnoses were not included but there should be no differ-
ence between people with or without an FH mutation in 
this respect. Information on AMI subtypes is not available. 
Further, important factors that influence AMI morbidity and 
hospitalisation frequencies were not accounted for, that is, 
smoking habits, body mass index, LDL-C values, statin treat-
ment, dietary habits or participation in coronary rehabilitation 
programmes after discharge. Patients were mainly Caucasian as 
92.4% of the patients in the FH cohort are native Norwegians. 
Error rates in Patient Administrative Data (PAS) were, for AMI 
and stroke, previously reported to be 0.8% and 0.9% for time of 
admission, 4.7% and 4.9% for the main diagnosis, and 1.7% and 
2.9% for index diagnosis, respectively.
Selection bias is important in register studies. Participants 
in the present study account for almost one-third of the total 
number of patients with FH in Norway, given a prevalence of 
1:300. A large proportion of the total number reduce the possi-
bility of any major selection bias. Further, most patients in the 
register were diagnosed by cascade screening due to family 
ties to an index patient. These patients are typically unaware 
of their FH prior to diagnosis, living normal lives without 
any special precautions further reducing the risk of any heavy 
selection bias in our cohort. Lastly, all physicians may request 
genetic testing of FH. Testing is free of charge for physicians and 
patients in Norway probably reducing the risk for bias due to 
economic issues.
Table 6 Total coronary revascularisation* during 2001–2009
Sex and age groups Incident cases Person years in 1000
Crude incidence rate per 1000 
person years (95% CI)
expected number of 
cases† SIr (95% CI)‡
Men
  25–39 10 3.1 3.2 (1.7 to 6.0) 0.6 16.0 (8.6 to 29.7)
  40–49 33 2.1 16.1 (11.4 to 22.6) 3.3 10.1 (7.2 to 14.2)
  50–59 34 1.3 25.6 (18.3 to 35.8) 6.0 5.7 (4.1 to 7.9)
  60–69 24 0.7 33.7 (22.6 to 50.3) 5.2 4.6 (3.1 to 6.8)
  70–79 11 0.3 42.7 (23.7 to 77.2) 2.3 4.7 (2.6 to 8.5)
  80+ 3 0.02 144.1 (46.5 to 446.7) 0.1 25.9 (8.4 to 80.3)
  Total 115 7.5 15.4 (12.8 to 18.5) 17.6 6.5 (5.5 to 7.9)
Women
  25–39 2 3.5 0.6 (0.1 to 2.3) 0.2 11.8 (2.9 to 47.1)
  40–49 12 2.4 5.1 (2.9 to 8.9) 0.8 15.5 (8.8 to 27.2)
  50–59 18 1.9 9.4 (4.9 to 15.0) 2.0 9.1 (5.7 to 14.4)
  60–69 19 1.1 17.5 (11.1 to 27.4) 2.6 7.5 (4.8 to 11.7)
  70–79 11 0.4 26.6 (14.8 to 48.1) 1.6 6.9 (3.8 to 12.4)
  80+ 0 0.1 0 0.3 –
  Total 62 9.4 6.6 (5.1 to 8.5) 7.4 8.4 (6.6 to 10.8)
Statistically significant results in bold. 
*Includes percutaneous coronary intervention and coronary artery bypass grafting.
†Age-standardised by indirect standardisation with reference rates for the total Norwegian population during 2001–2009 stratified by sex, calendar year and 1 year age groups.
SIR, standardised incidence ratio.
Key messages
What is already known on this subject?
 ► Familial hypercholesterolaemia (FH) leads to increased risk 
of coronary heart disease (CHD), but little data exist on the 
impact of age on the excess risk.
What does this study add?
 ► A particularly high excess risk of CHD in young patients 
with FH was observed. The standardised incidence ratio 
(95% CI) for CHD was highest among patients 25–39 years 
old; 11.1 (7.1–17.5) and 17.3 (9.6–31.2) in men and women, 
respectively. In all age groups combined, standardised 
incidence ratio was 4.2 (3.6–5.0) in men and 4.7 (3.9–5.7) in 
women.
how might this impact on clinical practice?
 ► The highest excess risk for cardiovascular disease was at age 
25–39 years. More action is needed to find and treat patients 
with FH early in life.
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In conclusion, Norwegian patients with FH have significantly 
higher incidences of AMI, CHD and related intervention proce-
dures than the general population. This is true although statins 
are widely used. The youngest age group had the highest excess 
risk, underlining the need for early diagnosis and preventive 
treatment in FH.
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